NCT04718727View on ClinicalTrials.gov

Olanzapine for the Prevention of Postoperative Nausea and Vomiting

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Postoperative Nausea
Interventions
DRUG

Placebo

oral Placebo tablets one-hour preoperatively

DRUG

5 mg Olanzapine Tablets

oral 5 mg Olanzapine tablets one-hour preoperatively

DRUG

10 mg Olanzapine Tablets

oral 10 mg Olanzapine tablets one-hour preoperatively

Trial Locations (2)

Egypt, 715715

Assiut university hospitals, Asyut

Unknown

Assiut university, Asyut

All Listed Sponsors
lead

Amani Hassan Abdel-Wahab

OTHER

NCT04718727 - Olanzapine for the Prevention of Postoperative Nausea and Vomiting | Biotech Hunter | Biotech Hunter